Get started
Capricor Therapeutics, Inc.Capricor Therapeutics, Inc.Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

CAPR trade ideas

CAPR Has The Potential For Big ProfitsHello, What is CAPR? Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. News Shares of Capricor Therapeutics Inc. (CAPR) are currently down despite the company announcing positive top-line results from a study of its lead candidate in the treatment of a muscle degeneration disorder. Clinical-stage biotechnology company Capricor Tuesday announced positive top-line 12-month results of the HOPE-2 clinical trial using CAP-1002 to treat patients in advanced stages of Duchenne muscular dystrophy (DMD). DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. Boys and young men typically lose their ability to walk in their teens and generally die of cardiac or respiratory complications in their 30s. The study data showed improvements in upper limb, cardiac, and respiratory function. My Thoughts For You Looking at the monthly time-frame you will see some wild price swings, I think we are due for another wild ride to the moon. Additionally, I would like to mention that this company is working on a vaccine for Covid-19. Good Luck, Cheers! Be sure to comment, follow, like, and check out my profile for more trade ideas!
NASDAQ:CAPRLong
by keifer
1
Correction revisitedIf you've followed my work, you know I'm debating between harmonic and classical EW theory. Harmonic is where 5 wave impulses are divided into 3 wave zigzags for waves 1,3,5. Upon further observation it may be that corrective structures like A waves or C waves in zigzags are actually better suited for the harmonic method of counting. Previously, I stated this was a complex WXYXZ correction that was playing out in CAPR because of the multiple zigzags, but in fact, what may be happening is the WXYXZ is the structure for the A wave. So WXYXZ is actually used to build the A wave of a zigzag. This may seem complex but it actually simplifies things a bit. CAPR made one leg down then we had a countertrend rally and now seem to be going down again. I will look for the C wave to follow the WXYXZ structure for completion.
NASDAQ:CAPR
by Sintar123
1
Capricorn Therapeutics Could be big mover Thursday $caprCapricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced that it will host a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on Thursday, March 26, 2020 at 12pm Eastern Time. The call will feature a presentation by KOL and newly appointed Capricor Executive Consultant Stephen J. Gould, Ph.D., from Johns Hopkins University, who will provide an overview of an exosome-based vaccine approach. Additionally, he will discuss the strategic plan to further develop the company's exosome platform technologies including its potential application as a COVID-19 vaccine. Capricor is committed to developing precision-engineered exosomes that carry defined sets of effector molecules which exert their effects through defined mechanisms of action. Source Business wire Company profile Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the companies investigating the field of extracellular vesicles and is exploring the potential of exosome-based candidates to treat a variety of disorders.
NASDAQ:CAPR
by Bullishcharts
1
Are New Highs In Store For CAPR?One of the penny stocks to watch due to its recent performance is that of Capricor Therapeutics Inc (CAPR Stock Report). Back on September 24, the company had been granted a meeting by the United States Food and Drug Administration. " Shares gained as much as 20% as Capricor stock started the week with a bang. It is one of the biotech penny stocks that have performed impressively over recent days. Obviously with news like this and the type of momentum CAPR stock is seeing, many will have it on their watch lists for the week. " Source: 3 Penny Stocks To Buy or Sell In October?
NASDAQ:CAPR
by PennyStocks101
2
$CAPR BUILDING FOR A BREAKOUT ON STRONG VOLUME. *******ALERTED TO CAPR ON SPECULATION AND RUMOR WITH HIGH VOLUME AND PRICE SPIKE TO CONFIRM INTEREST, ON CLOSE WATCH FOR COMING DAYS***** AVERAGE ANALYSTS PRICE TARGET $35 AVERAGE ANALYSTS RECOMMENDATION COMPANY PROFILE Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
NASDAQ:CAPRLong
by DEXWireNews
CAPR - Fallen angel breakout long from $1.53 to $2.57CARP is a advanced/aggressive long setup. It has broken out on huge volume yesterday and forming a flag formation in hourly frame. We think it has further upside potential. * Trade Criteria * Date First Found- July 18, 2017 Pattern/Why- Fallen angel breakout Long (advanced/aggressive setup) Entry Target Criteria- Break of $1.53 Exit Target Criteria- $1.83, $1.87, 2nd Target $2.57 Stop Loss Criteria- $1.24 Please check back for Trade updates. (Note: Trade update is little delayed here.)
NASDAQ:CAPRLong
by AcornWealthCorp